1. [CASE 1 — QUESTION 1]
A 26-year-old woman, J.M., presents with a six-week history of bloody diarrhea, urgency, and crampy left lower-quadrant pain. Colonoscopy shows continuous mucosal inflammation extending from the rectum to the splenic flexure, consistent with moderately active left-sided ulcerative colitis. She has no prior inflammatory bowel disease treatment and wishes to avoid systemic corticosteroids if possible. Considering disease extent and the principle that clinical benefit in ulcerative colitis tracks with mucosal 5-aminosalicylic acid concentration at the inflamed segment, which initial regimen is most appropriate?
A) Oral prednisone 40 mg daily as first-line therapy
B) A mesalamine suppository alone
C) Combined oral mesalamine plus a rectal mesalamine enema
D) Oral azathioprine monotherapy for rapid induction
E) Intravenous methylprednisolone
ANSWER: C
Rationale:
For moderately active left-sided ulcerative colitis, guideline-based first-line therapy is combined oral mesalamine plus a rectal mesalamine enema. The combination raises mucosal 5-aminosalicylic acid concentration across the left colon more than either route alone, achieving faster symptom response and higher endoscopic remission rates while sparing systemic corticosteroid exposure. An enema reaches the left colon to the splenic flexure, matching this patient's disease extent.
Option A: Option A is incorrect: systemic prednisone carries corticosteroid toxicity, has no maintenance role, and is not first-line for disease that should respond to optimized 5-aminosalicylic acid therapy.
Option B: Option B is incorrect: a suppository reaches only the rectum and distal 10 to 15 cm, so it would not cover disease extending to the splenic flexure.
Option D: Option D is incorrect: thiopurines take 3 to 6 months to act and cannot induce remission, so azathioprine monotherapy would leave active disease untreated.
Option E: Option E is incorrect: intravenous methylprednisolone is reserved for severe acute colitis, not moderate ambulatory disease.
2. [CASE 1 — QUESTION 2]
Continuing with the same patient. Before finalizing the regimen, a colleague suggests using sulfasalazine instead of a sulfa-free mesalamine product because it is inexpensive. J.M. is of Mediterranean descent and is planning a pregnancy within the year. Which consideration most appropriately guides the choice between sulfasalazine and a sulfapyridine-free mesalamine formulation?
A) A sulfapyridine-free mesalamine formulation avoids the sulfapyridine carrier responsible for most sulfasalazine toxicity, including oxidative hemolysis in glucose-6-phosphate dehydrogenase (G6PD) deficiency; if sulfasalazine is considered, G6PD screening should precede it, and her Mediterranean ancestry raises that concern
B) Sulfasalazine is preferred in women planning pregnancy because the sulfapyridine carrier improves fetal outcomes
C) The two agents are pharmacologically identical, so cost alone should decide
D) Sulfasalazine has no effect on folate status, so no supplementation is needed with either agent
E) A sulfapyridine-free formulation carries the same hemolysis risk as sulfasalazine, so neither is safe in this patient
ANSWER: A
Rationale:
The therapeutic activity of sulfasalazine resides in the 5-aminosalicylic acid moiety, while the sulfapyridine carrier accounts for most adverse effects, including oxidative hemolysis in glucose-6-phosphate dehydrogenase (G6PD) deficiency. A sulfapyridine-free mesalamine formulation avoids this carrier. In a patient of Mediterranean descent (higher G6PD-deficiency prevalence), if sulfasalazine were considered, G6PD screening should precede it; choosing a sulfa-free product sidesteps that risk altogether and also avoids the carrier-related folate malabsorption relevant to a planned pregnancy.
Option B: Option B is incorrect: the sulfapyridine carrier does not improve fetal outcomes and adds toxicity.
Option C: Option C is incorrect: the agents are not identical—sulfasalazine carries sulfapyridine and its toxicities—so cost alone is not an adequate basis.
Option D: Option D is incorrect: sulfasalazine impairs intestinal folate absorption and requires folic acid supplementation, which is particularly important before pregnancy.
Option E: Option E is incorrect: the hemolysis risk derives from sulfapyridine, so a sulfa-free formulation does not carry that risk.
3. [CASE 1 — QUESTION 3]
Continuing with the same patient. Suppose sulfasalazine was started without prior screening. Ten days later J.M. returns with fatigue, jaundice, and dark urine; hemoglobin has fallen, the reticulocyte count is elevated, and the peripheral smear shows bite cells. What is the correct interpretation and immediate action?
A) This is expected dose-related nausea from sulfapyridine; continue the drug and add an antiemetic
B) This is a folate-deficiency megaloblastic anemia; increase the sulfasalazine dose and add folic acid
C) This is an immune-mediated agranulocytosis; continue sulfasalazine with growth factor support
D) This is acute oxidative hemolytic anemia from the sulfapyridine carrier in an undiagnosed glucose-6-phosphate dehydrogenase (G6PD) deficient patient; stop sulfasalazine and switch to a sulfapyridine-free mesalamine formulation
E) This is hepatotoxicity from the 5-aminosalicylic acid moiety; reduce the dose and monitor liver enzymes
ANSWER: D
Rationale:
Jaundice, dark urine, falling hemoglobin, reticulocytosis, and bite cells indicate acute hemolytic anemia. In a patient of Mediterranean descent this points to glucose-6-phosphate dehydrogenase (G6PD) deficiency, in which the oxidant sulfapyridine carrier of sulfasalazine precipitates hemolysis. The correct action is to stop sulfasalazine and switch to a sulfapyridine-free mesalamine formulation.
Option A: Option A is incorrect: the findings are hemolysis, not simple nausea, and continuing the drug would be dangerous.
Option B: Option B is incorrect: reticulocytosis and bite cells indicate hemolysis, not megaloblastic anemia, and increasing the dose would worsen it.
Option C: Option C is incorrect: the picture is hemolytic anemia, not agranulocytosis, and continuing the offending drug is inappropriate.
Option E: Option E is incorrect: the hemolysis arises from the sulfapyridine carrier, not the 5-aminosalicylic acid moiety, so dose reduction without stopping the drug does not address the mechanism.
4. [CASE 1 — QUESTION 4]
Continuing with the same patient. After switching to a sulfapyridine-free mesalamine and adding a rectal enema, J.M. achieves clinical and endoscopic remission. She asks about long-term therapy and admits she often forgets midday doses. Which statement best guides maintenance planning?
A) Mesalamine has no role in ulcerative colitis maintenance, so therapy should be stopped once remission is achieved
B) Mesalamine is effective for ulcerative colitis maintenance, adherence is a major predictor of sustained remission, and a once-daily multi-matrix (MMX) formulation can improve adherence compared with multiple daily doses
C) Long-term low-dose prednisone is the preferred maintenance strategy to prevent relapse
D) She should transition to azathioprine for maintenance because mesalamine cannot maintain remission in ulcerative colitis
E) Maintenance is unnecessary because a single course of induction therapy cures ulcerative colitis
ANSWER: B
Rationale:
5-Aminosalicylic acid agents are effective for both induction and maintenance of remission in ulcerative colitis, and adherence is one of the strongest predictors of sustained remission. For a patient who forgets midday doses, a once-daily multi-matrix (MMX) mesalamine formulation can improve adherence relative to older three- or four-times-daily regimens.
Option A: Option A is incorrect: mesalamine is a cornerstone of ulcerative colitis maintenance, not solely an induction agent.
Option C: Option C is incorrect: corticosteroids have no maintenance role and carry cumulative toxicity.
Option D: Option D is incorrect: mesalamine does maintain ulcerative colitis remission, so escalation to a thiopurine is not required for a patient doing well on 5-aminosalicylic acid.
Option E: Option E is incorrect: ulcerative colitis is a chronic relapsing disease; maintenance therapy is needed to sustain remission.
5. [CASE 2 — QUESTION 1]
A 34-year-old man, R.T., presents with several weeks of right lower-quadrant pain, non-bloody diarrhea, and a 4 kg weight loss. Colonoscopy and imaging show mild-to-moderate Crohn's disease limited to the terminal ileum and cecum. He is otherwise healthy. To induce remission while minimizing systemic corticosteroid effects, which agent is most appropriate first-line?
A) Oral mesalamine, because it is highly effective for ileal Crohn's disease
B) Intravenous methylprednisolone, because all Crohn's disease requires systemic steroids
C) Long-term oral prednisone as maintenance therapy
D) Azathioprine alone for rapid induction of remission
E) Oral budesonide controlled-ileal-release 9 mg daily, which targets the ileocecal region and undergoes extensive first-pass hepatic metabolism, limiting systemic corticosteroid exposure
ANSWER: E
Rationale:
For mild-to-moderate Crohn's disease limited to the ileum and right colon, budesonide controlled-ileal-release 9 mg daily is preferred over systemic prednisone. It releases in the ileocecal region to act locally and undergoes extensive first-pass hepatic metabolism (predominantly by CYP3A4), giving low systemic bioavailability and substantially fewer systemic corticosteroid effects.
Option A: Option A is incorrect: 5-aminosalicylic acid agents have limited efficacy in Crohn's disease and are not reliably effective for ileal Crohn's induction.
Option B: Option B is incorrect: intravenous steroids are reserved for severe disease, not mild-to-moderate ambulatory ileocecal Crohn's.
Option C: Option C is incorrect: corticosteroids have no maintenance role and cause cumulative toxicity.
Option D: Option D is incorrect: thiopurines have a delayed onset of months and cannot induce remission, so azathioprine alone would leave active disease untreated.
6. [CASE 2 — QUESTION 2]
Continuing with the same patient. R.T. asks why budesonide is less likely than prednisone to cause the steroid side effects he has read about. Which explanation is correct?
A) Budesonide binds the glucocorticoid receptor far more weakly than prednisone, so it has little effect anywhere
B) Budesonide undergoes extensive first-pass hepatic metabolism (mainly by CYP3A4), giving an oral systemic bioavailability of only about 10 to 15 percent versus roughly 80 to 100 percent for prednisone, so less active drug reaches the systemic circulation
C) Budesonide is not absorbed from the gut and therefore cannot cause systemic effects
D) Budesonide is eliminated unchanged by the kidney before it can act systemically
E) Budesonide and prednisone have identical bioavailability, and the difference is only in tablet size
ANSWER: B
Rationale:
Budesonide is well absorbed but then undergoes extensive first-pass hepatic metabolism, predominantly by CYP3A4 (cytochrome P450 3A4), yielding an oral systemic bioavailability of only about 10 to 15 percent, compared with roughly 80 to 100 percent for prednisone. Less active drug reaches the systemic circulation, which is why budesonide produces fewer systemic corticosteroid effects despite high local potency.
Option A: Option A is incorrect: budesonide actually has high glucocorticoid receptor affinity and strong local potency, so weak binding is not the explanation.
Option C: Option C is incorrect: budesonide is absorbed; its safety derives from hepatic first-pass clearance after absorption, not from a lack of absorption.
Option D: Option D is incorrect: budesonide is cleared by hepatic metabolism, not by renal elimination of unchanged drug.
Option E: Option E is incorrect: the two drugs differ markedly in bioavailability because of first-pass metabolism, not in tablet dimensions.
7. [CASE 2 — QUESTION 3]
Continuing with the same patient. While on budesonide, R.T. is prescribed itraconazole (a potent inhibitor of the liver enzyme CYP3A4) for a fungal nail infection. Three weeks later he develops moon facies and elevated blood glucose. What is the explanation and the appropriate response?
A) Itraconazole inhibited CYP3A4-mediated first-pass metabolism of budesonide, raising its systemic exposure and producing systemic corticosteroid effects; reduce or stop budesonide or choose a non-interacting antifungal
B) Itraconazole accelerated budesonide clearance, lowering its levels and causing steroid withdrawal
C) The findings are unrelated to either drug and indicate primary Cushing disease
E) Itraconazole inactivated budesonide in the gut, eliminating both local and systemic effects
ANSWER: A
Rationale:
Budesonide's low systemic exposure depends on first-pass metabolism by CYP3A4. A potent CYP3A4 inhibitor such as itraconazole blocks that clearance, allowing more intact budesonide into the systemic circulation and producing systemic corticosteroid effects such as moon facies and hyperglycemia. The appropriate response is to reduce or stop budesonide or select a non-interacting antifungal.
Option B: Option B is incorrect: CYP3A4 inhibition reduces metabolism and raises exposure, so clearance is not accelerated.
Option C: Option C is incorrect: the temporal relationship to itraconazole and the known interaction make primary Cushing disease an unnecessary explanation.
Option D: Option D is incorrect: systemic exposure rose, not fell; a fall would not cause steroid excess.
Option E: Option E is incorrect: itraconazole raises active budesonide levels by inhibiting metabolism rather than inactivating the drug in the gut.
8. [CASE 2 — QUESTION 4]
Continuing with the same patient. Over the next year, R.T. relapses each time budesonide is tapered below a maintenance dose, and he has now required steroids twice. Which management principle is correct?
A) Continue budesonide indefinitely as maintenance, since it has no systemic effects at any duration
B) Restart full systemic prednisone and continue it long term to prevent relapse
C) Mesalamine should be substituted as maintenance, since it is equivalent to immunomodulators for Crohn's disease
D) He now meets the definition of steroid-dependent Crohn's disease, which is an indication to escalate to a steroid-sparing immunomodulator (a thiopurine or methotrexate) or a biologic, because corticosteroids cannot maintain remission
E) No change is needed; repeated steroid courses are an acceptable long-term strategy
ANSWER: D
Rationale:
A patient who relapses whenever steroids are tapered, or who needs steroids more than once per year, meets the definition of steroid-dependent disease. Because corticosteroids—including budesonide—do not maintain remission and carry cumulative toxicity, steroid dependence is an indication to escalate to a steroid-sparing immunomodulator (a thiopurine or methotrexate) or a biologic.
Option A: Option A is incorrect: budesonide is not free of systemic effects with prolonged use and is not a maintenance agent.
Option B: Option B is incorrect: long-term systemic prednisone causes cumulative toxicity and does not alter disease course.
Option C: Option C is incorrect: mesalamine lacks proven efficacy for Crohn's maintenance and is not equivalent to immunomodulators.
Option E: Option E is incorrect: repeated steroid courses are precisely the pattern that should trigger escalation, not an acceptable long-term plan.
9. [CASE 3 — QUESTION 1]
A 30-year-old woman, L.K., with steroid-dependent Crohn's disease is to begin azathioprine as a steroid-sparing maintenance agent. She is bridged with budesonide while the thiopurine takes effect. Before the first dose, which pre-treatment testing is required to reduce the risk of severe myelosuppression?
A) Testing both thiopurine S-methyltransferase (TPMT) and NUDT15 (nudix hydrolase 15), because each independently predicts thiopurine myelotoxicity and poor-metabolizer or loss-of-function results require major dose reduction or an alternative agent
B) Testing glucose-6-phosphate dehydrogenase (G6PD) only, because thiopurines cause oxidative hemolysis
C) Testing CYP3A4 genotype, because thiopurines are activated by that enzyme
D) No testing is required because myelosuppression cannot be predicted
E) Measuring a baseline 6-thioguanine nucleotide level before the first dose to set the starting dose
ANSWER: A
Rationale:
Before initiating a thiopurine, both TPMT (thiopurine S-methyltransferase) and NUDT15 (nudix hydrolase 15) should be tested, because each independently predicts myelotoxicity. Poor-metabolizer TPMT status and loss-of-function NUDT15 status call for major dose reduction or an alternative agent.
Option B: Option B is incorrect: G6PD screening addresses oxidative hemolysis with sulfapyridine-containing sulfasalazine, not thiopurine myelosuppression.
Option C: Option C is incorrect: thiopurines are not activated by CYP3A4, so CYP3A4 genotyping does not predict their toxicity.
Option D: Option D is incorrect: myelotoxicity risk can be predicted pharmacogenomically, which is the entire purpose of pre-treatment testing.
Option E: Option E is incorrect: a baseline 6-thioguanine nucleotide level cannot be obtained before any drug is given, since that metabolite forms only after dosing; it is a monitoring tool, not a pre-treatment test.
10. [CASE 3 — QUESTION 2]
Continuing with the same patient. Testing returns a normal NUDT15 genotype but an intermediate thiopurine S-methyltransferase (TPMT) result (one functional and one non-functional allele). How should azathioprine be dosed?
A) Avoid thiopurines entirely, because intermediate metabolizers cannot tolerate any dose
B) Use the full standard dose, because only poor metabolizers require any change
C) Reduce the starting dose by roughly 30 to 50 percent and monitor the complete blood count closely, because intermediate metabolizers accumulate higher active metabolite levels than normal metabolizers
D) Increase the dose above standard, because intermediate metabolizers clear the drug faster
E) Give the standard dose but add allopurinol routinely to all intermediate metabolizers
ANSWER: C
Rationale:
TPMT (thiopurine S-methyltransferase) intermediate metabolizers carry one non-functional allele and shunt somewhat more 6-mercaptopurine toward active 6-thioguanine nucleotides than normal metabolizers, raising myelotoxicity risk. The appropriate approach is to reduce the starting dose by roughly 30 to 50 percent with close complete blood count monitoring.
Option A: Option A is incorrect: intermediate metabolizers can usually receive a thiopurine at reduced dose; only poor metabolizers generally require avoidance or drastic reduction.
Option B: Option B is incorrect: intermediate metabolizers do require dose adjustment, not full standard dosing.
Option D: Option D is incorrect: intermediate metabolizers accumulate more active metabolite, not less, so the dose should be reduced rather than increased.
Option E: Option E is incorrect: routine allopurinol is not indicated for all intermediate metabolizers and would itself require major dose reduction to avoid toxicity.
11. [CASE 3 — QUESTION 3]
Continuing with the same patient. After dose adjustment, L.K. still has active disease despite further dose increases. Metabolite testing shows markedly elevated 6-methylmercaptopurine with low active 6-thioguanine nucleotides, and her transaminases are now twice the upper limit of normal. What does this metabolite pattern represent?
A) Optimal dosing requiring no change, since both metabolites are within target
B) Non-adherence, since both metabolites are undetectable
C) A thiopurine S-methyltransferase poor-metabolizer pattern with dangerously high 6-thioguanine nucleotides
D) Rapid catabolism by xanthine oxidase generating excess thiouric acid with no clinical consequence
E) Preferential methylation, in which the 6-methylmercaptopurine pathway predominates—causing hepatotoxicity and therapeutic failure despite adequate or escalating dosing
ANSWER: E
Rationale:
A pattern of high 6-methylmercaptopurine with low active 6-thioguanine nucleotides is preferential methylation. It produces hepatotoxicity (from the elevated methylated metabolite) and therapeutic failure (from inadequate active metabolite) even as the dose is escalated, exactly matching L.K.'s rising transaminases and persistent disease activity.
Option A: Option A is incorrect: the metabolites are not balanced or in target; the active metabolite is low while the methylated metabolite is high.
Option B: Option B is incorrect: the metabolites are not undetectable—one is markedly elevated—so non-adherence does not fit.
Option C: Option C is incorrect: a poor-metabolizer pattern shows high 6-thioguanine nucleotides, the opposite of this low-6-thioguanine-nucleotide picture.
Option D: Option D is incorrect: this pattern reflects excess methylation rather than excess thiouric acid, and it carries clear clinical consequences (hepatotoxicity and failure).
12. [CASE 3 — QUESTION 4]
Continuing with the same patient. The team wishes to salvage thiopurine therapy rather than abandon it. Which intervention correctly addresses both the hepatotoxicity and the therapeutic failure caused by preferential methylation?
A) Double the azathioprine dose to force more active metabolite formation
B) Add low-dose allopurinol (a xanthine oxidase inhibitor) and simultaneously reduce the azathioprine dose to roughly 25 to 33 percent, redirecting metabolism toward active 6-thioguanine nucleotides and away from the hepatotoxic methylated metabolite, with intensified complete blood count monitoring
C) Add full-dose allopurinol without changing the azathioprine dose
D) Continue the current dose and add a hepatoprotective supplement without other change
E) Stop azathioprine and treat the Crohn's disease with allopurinol monotherapy
ANSWER: B
Rationale:
Adding low-dose allopurinol inhibits xanthine oxidase and shifts thiopurine metabolism away from the methylation route toward active 6-thioguanine nucleotides, correcting both the hepatotoxicity and the therapeutic failure of preferential methylation. Because this sharply increases active metabolite formation, the azathioprine dose must be reduced to roughly 25 to 33 percent with intensified complete blood count monitoring.
Option A: Option A is incorrect: doubling the dose worsens 6-methylmercaptopurine-driven hepatotoxicity without fixing the shunting.
Option C: Option C is incorrect: adding allopurinol without reducing the thiopurine dose risks fatal 6-thioguanine nucleotide accumulation and myelosuppression.
Option D: Option D is incorrect: leaving the dose unchanged ignores the correctable metabolic problem and ongoing hepatotoxicity.
Option E: Option E is incorrect: allopurinol is not a treatment for Crohn's disease and cannot serve as monotherapy.
13. [CASE 4 — QUESTION 1]
A 28-year-old man, D.S., with known ulcerative colitis is admitted with 12 bloody stools per day, fever, tachycardia, and elevated C-reactive protein. He is diagnosed with severe acute ulcerative colitis. After excluding infection, which initial pharmacologic therapy is most appropriate?
A) Oral budesonide controlled-ileal-release 9 mg daily
B) Oral mesalamine combined with a rectal enema
C) Outpatient oral prednisone with next-week follow-up
D) Intravenous corticosteroids—hydrocortisone about 300 mg/day in divided doses or methylprednisolone about 40 to 60 mg/day
E) Immediate azathioprine monotherapy to induce remission
ANSWER: D
Rationale:
Severe acute ulcerative colitis requiring hospitalization is treated first with intravenous corticosteroids—hydrocortisone about 300 mg/day in divided doses or methylprednisolone about 40 to 60 mg/day—after infection has been excluded.
Option A: Option A is incorrect: oral budesonide is a topically acting agent for mild-to-moderate disease and is inadequate for severe acute colitis.
Option B: Option B is incorrect: oral plus rectal 5-aminosalicylic acid is first-line for mild-to-moderate disease, not for a severe acute flare.
Option C: Option C is incorrect: outpatient management is unsafe for severe acute colitis, which requires inpatient intravenous therapy and close monitoring.
Option E: Option E is incorrect: thiopurines take months to act and cannot induce remission in an acute severe flare.
14. [CASE 4 — QUESTION 2]
Continuing with the same patient. D.S. is started on intravenous methylprednisolone. The team plans the timing of the response assessment that will determine whether rescue therapy is needed. When should the formal assessment of corticosteroid response occur?
A) At 24 hours, with rescue therapy started immediately if any bloody stool persists
B) At day 3, using validated clinical indices, because non-response by then identifies patients who should be considered for rescue therapy rather than prolonged steroids
C) Only after 14 days of intravenous steroids
D) After discharge, at the first outpatient visit
E) No formal assessment is needed; steroids are simply continued until symptoms resolve
ANSWER: B
Rationale:
In severe acute ulcerative colitis, response to intravenous corticosteroids is formally assessed at day 3 using validated clinical indices. Non-response by day 3 identifies patients who should be considered for rescue therapy rather than continued ineffective steroids.
Option A: Option A is incorrect: 24 hours is too early for a definitive response assessment, and isolated persistence of a bloody stool at one day is not the defined trigger.
Option C: Option C is incorrect: waiting 14 days dangerously delays escalation and prolongs ineffective steroid exposure.
Option D: Option D is incorrect: the assessment is an inpatient decision point during the acute admission, not a post-discharge step.
Option E: Option E is incorrect: a structured day-3 assessment is precisely what guides timely escalation; simply continuing steroids indefinitely is unsafe.
15. [CASE 4 — QUESTION 3]
Continuing with the same patient. On day 3, D.S. has shown no meaningful improvement and continues to pass frequent bloody stools. Which is the most appropriate next step?
A) Continue intravenous methylprednisolone unchanged for another week
B) Switch to oral budesonide and arrange discharge
C) Initiate rescue therapy with infliximab or intravenous cyclosporine
D) Begin azathioprine to induce remission over the coming days
E) Add adrenocorticotropic hormone (ACTH) to stimulate cortisol output
ANSWER: C
Rationale:
A day-3 non-responder with severe acute ulcerative colitis should be moved to rescue therapy—infliximab or intravenous cyclosporine—rather than continuing ineffective steroids beyond roughly 5 to 7 days, because delay increases the risk of complications and colectomy.
Option A: Option A is incorrect: prolonging unchanged steroids in a non-responder is exactly what should be avoided.
Option B: Option B is incorrect: oral budesonide is inadequate for steroid-refractory severe colitis and discharge would be unsafe.
Option D: Option D is incorrect: thiopurines act over months and cannot rescue an acute severe flare.
Option E: Option E is incorrect: ACTH has been abandoned in favor of direct corticosteroids and is not appropriate rescue therapy.
16. [CASE 4 — QUESTION 4]
Continuing with the same patient. D.S. is started on infliximab rescue therapy. The team counsels him about prognosis and the role of surgery. Which statement most accurately frames the situation?
A) Rescue therapy guarantees colectomy will be avoided, so surgical consultation is unnecessary
B) Colectomy is required immediately in all patients who fail day-3 steroids, regardless of rescue therapy response
C) Rescue therapy should be continued indefinitely even without response, since surgery is never appropriate in ulcerative colitis
D) Infliximab rescue eliminates the need for any further monitoring of disease activity
E) A substantial proportion of patients with severe acute ulcerative colitis—roughly 30 to 40 percent—ultimately require colectomy if rescue therapy also fails, so response to rescue must be monitored closely and surgical consultation involved early
ANSWER: E
Rationale:
Even with rescue therapy, roughly 30 to 40 percent of patients with severe acute ulcerative colitis ultimately require colectomy if the rescue agent also fails. Therefore response to rescue therapy must be monitored closely and surgical consultation involved early so that colectomy is not delayed in a deteriorating patient.
Option A: Option A is incorrect: rescue therapy does not guarantee colectomy avoidance, and surgical consultation is important.
Option B: Option B is incorrect: colectomy is not mandatory for every day-3 steroid failure; rescue therapy is tried first, with surgery for rescue failure or deterioration.
Option C: Option C is incorrect: continuing ineffective rescue therapy indefinitely is unsafe, and colectomy is an appropriate, sometimes life-saving option in ulcerative colitis.
Option D: Option D is incorrect: ongoing close monitoring remains essential after starting rescue therapy.
17. [CASE 5 — QUESTION 1]
A 42-year-old man, P.N., with moderate-to-severe Crohn's disease previously stopped azathioprine because of intolerance. He is now beginning infliximab. The team wants to reduce anti-drug antibody formation that could shorten the biologic's durability. Drawing on the SONIC trial (which showed combination azathioprine plus infliximab superior to either agent alone in Crohn's disease), which approach is best?
A) Use infliximab monotherapy, because adding any immunomodulator offers no benefit
B) Combine infliximab with low-dose methotrexate as the immunomodulator companion, applying the SONIC principle that an immunomodulator reduces anti-drug antibody formation and improves durability, with methotrexate chosen because of his thiopurine intolerance
C) Restart full-dose azathioprine despite the documented intolerance
D) Pair the biologic with long-term prednisone to suppress antibody formation
E) Delay the biologic for a year of observation before starting any companion
ANSWER: B
Rationale:
SONIC (trial showing combination azathioprine plus infliximab superior to either agent alone in Crohn's disease) established that pairing an immunomodulator with an anti-tumor necrosis factor biologic reduces anti-drug antibody formation and improves durability. Because P.N. cannot tolerate a thiopurine, low-dose methotrexate is the reasonable immunomodulator companion, transferring the SONIC principle to an agent he can take.
Option A: Option A is incorrect: combination therapy reduces immunogenicity and outperforms monotherapy for antibody reduction.
Option C: Option C is incorrect: restarting a drug he is documented to be intolerant of is inappropriate when an alternative exists.
Option D: Option D is incorrect: corticosteroids have no maintenance role and are not the immunomodulator companion that lowers biologic immunogenicity.
Option E: Option E is incorrect: delaying treatment for a year contradicts the need to control moderate-to-severe disease and offers no immunogenicity benefit.
18. [CASE 5 — QUESTION 2]
Continuing with the same patient. P.N. asks how methotrexate works for his bowel disease when he knows it is also a cancer drug. Which explanation correctly distinguishes its low-dose anti-inflammatory action from its high-dose cytotoxic action?
A) Both effects come entirely from inhibition of dihydrofolate reductase, differing only in degree
B) The anti-inflammatory effect comes from incorporation of methotrexate into DNA, while the cytotoxic effect raises adenosine
C) Both effects come from neutralization of tumor necrosis factor-alpha
D) The anti-inflammatory effect comes from blocking the folate carrier transporter in the gut
E) At low weekly doses the predominant anti-inflammatory effect is accumulation of methotrexate polyglutamates that inhibit AICAR transformylase and raise extracellular adenosine, whereas the high-dose cytotoxic effect is inhibition of dihydrofolate reductase depleting tetrahydrofolate for purine and thymidylate synthesis
ANSWER: E
Rationale:
At high (chemotherapeutic) doses, methotrexate inhibits dihydrofolate reductase, depleting tetrahydrofolate needed for purine and thymidylate synthesis—a cytotoxic effect. At the low weekly doses used in inflammatory bowel disease, the predominant anti-inflammatory mechanism is accumulation of methotrexate polyglutamates that inhibit AICAR (5-aminoimidazole-4-carboxamide ribonucleotide) transformylase, raising extracellular adenosine, which suppresses immune-cell function.
Option A: Option A is incorrect: the two actions are mechanistically distinct, not merely different degrees of dihydrofolate reductase inhibition.
Option B: Option B is incorrect: methotrexate is not incorporated into DNA the way thiopurine metabolites are; the low-dose effect is adenosine-mediated.
Option C: Option C is incorrect: methotrexate does not neutralize tumor necrosis factor-alpha, which is the action of anti-TNF biologics.
Option D: Option D is incorrect: the folate carrier governs methotrexate absorption, not its anti-inflammatory mechanism.
19. [CASE 5 — QUESTION 3]
Continuing with the same patient. The team plans methotrexate 25 mg once weekly and chooses subcutaneous injection rather than oral tablets. What is the pharmacokinetic rationale?
A) Oral methotrexate absorption occurs through a saturable folate carrier transporter, so bioavailability is variable and declines at doses above about 15 mg; subcutaneous administration bypasses this step and gives reliable systemic exposure
B) Oral methotrexate is completely destroyed by gastric acid, so no drug is absorbed by mouth
C) Oral methotrexate has perfectly predictable 100 percent bioavailability, so the route is chosen only for convenience
D) Methotrexate cannot enter cells when taken orally, unlike the injected form
E) Oral methotrexate undergoes near-complete first-pass hepatic inactivation, leaving no active drug
ANSWER: A
Rationale:
Oral methotrexate is absorbed via a saturable folate carrier transporter; because the transporter saturates, oral bioavailability is variable and falls at doses above roughly 15 mg. Subcutaneous (or intramuscular) administration bypasses this saturable absorption step and provides reliable, consistently high systemic exposure at the 25 mg weekly dose.
Option B: Option B is incorrect: the limitation is saturable carrier-mediated absorption, not gastric acid destruction.
Option C: Option C is incorrect: oral bioavailability is variable, not a predictable 100 percent, so the choice is pharmacologic rather than mere convenience.
Option D: Option D is incorrect: methotrexate enters cells by carrier transport regardless of route, so the preference reflects absorption reliability.
Option E: Option E is incorrect: oral methotrexate is not subject to near-complete first-pass hepatic inactivation; the variability arises at the absorption step.
20. [CASE 5 — QUESTION 4]
Continuing with the same patient. The team prescribes folic acid alongside weekly methotrexate. P.N. worries the folate will cancel the drug's benefit. Which explanation is correct?
A) Folate will reverse the benefit, because both the toxic and anti-inflammatory effects depend on dihydrofolate reductase inhibition
B) Folate increases methotrexate cytotoxicity and should be avoided in inflammatory bowel disease
C) Folate reduces dihydrofolate-reductase-driven toxicities such as mucositis and cytopenias without blunting efficacy, because the low-dose anti-inflammatory effect is adenosine-mediated and folate-independent
D) Folate converts methotrexate into a more potent dihydrofolate reductase inhibitor, raising both efficacy and toxicity
E) Folate has no effect on methotrexate toxicity and is prescribed only by tradition
ANSWER: C
Rationale:
Methotrexate's troublesome low-dose toxicities—mucositis, nausea, cytopenias—arise from dihydrofolate reductase inhibition in rapidly dividing non-immune tissues, and folate repletion mitigates exactly these effects. The low-dose anti-inflammatory benefit operates through the adenosine pathway, which is folate-independent, so supplementation reduces toxicity while preserving efficacy.
Option A: Option A is incorrect: the anti-inflammatory effect is not driven by dihydrofolate reductase inhibition, so folate does not reverse it.
Option B: Option B is incorrect: folate reduces, rather than increases, methotrexate toxicity.
Option D: Option D is incorrect: folate does not make methotrexate a stronger dihydrofolate reductase inhibitor; it replenishes the folate pool the drug depletes.
Option E: Option E is incorrect: folate meaningfully lowers methotrexate toxicity and is given for that reason, not merely by tradition.
21. [CASE 6 — QUESTION 1]
A 29-year-old woman, A.B., with Crohn's disease needs a steroid-sparing maintenance immunomodulator. She has normal thiopurine S-methyltransferase and NUDT15 testing and hopes to conceive within about a year. Considering reproductive plans alongside drug properties, which statement most appropriately guides the choice?
A) Methotrexate is preferred because its pregnancy safety profile is superior to that of thiopurines
B) Either agent is equivalent, and reproductive plans have no bearing on the choice
C) Methotrexate should be started now because contraception is unnecessary during therapy
D) Methotrexate is teratogenic and abortifacient and requires reliable contraception with discontinuation well before conception, so for a woman planning pregnancy a thiopurine is the more appropriate steroid-sparing choice given her normal pharmacogenomic testing
E) No immunomodulator should be used in any woman of reproductive age
ANSWER: D
Rationale:
Methotrexate is teratogenic and abortifacient, requires reliable contraception during therapy, and must be discontinued well before planned conception (generally at least 3 months). For a woman of reproductive age who hopes to conceive within a year, this makes methotrexate a poor choice; with normal TPMT and NUDT15 testing, a thiopurine is the more appropriate steroid-sparing maintenance agent.
Option A: Option A is incorrect: methotrexate's pregnancy profile is unfavorable, not superior.
Option B: Option B is incorrect: reproductive plans strongly influence the choice because of methotrexate's teratogenicity.
Option C: Option C is incorrect: contraception is mandatory during methotrexate therapy, so starting it without contraception in a woman planning pregnancy is unsafe.
Option E: Option E is incorrect: thiopurines can be used in women of reproductive age, so withholding all immunomodulators is unnecessary.
22. [CASE 6 — QUESTION 2]
Continuing with the same patient. Suppose A.B. had instead been placed on long-term methotrexate before her pregnancy plans changed. Which chronic organ toxicity most requires structured monitoring, and how is it monitored?
A) Hepatotoxicity (dose-dependent hepatic fibrosis), monitored with alanine aminotransferase and aspartate aminotransferase at baseline and every 4 to 8 weeks, with non-invasive fibrosis assessment as cumulative dose rises
B) Nephrotoxicity, monitored with weekly 24-hour urine protein collections
C) Cardiotoxicity, monitored with serial echocardiography every 4 weeks
D) Ototoxicity, monitored with quarterly audiometry
E) Pulmonary fibrosis, monitored with monthly spirometry as the primary surveillance tool
ANSWER: A
Rationale:
The most important chronic toxicity of methotrexate in inflammatory bowel disease is dose-dependent hepatic fibrosis. Monitoring uses liver function tests—alanine aminotransferase and aspartate aminotransferase—at baseline and every 4 to 8 weeks, with non-invasive fibrosis assessment (transient elastography or the FIB-4 index) as cumulative dose rises.
Option B: Option B is incorrect: although methotrexate is renally eliminated and accumulates in renal impairment, the central chronic monitoring concern is hepatic fibrosis, not a primary nephrotoxicity tracked by weekly urine protein.
Option C: Option C is incorrect: cardiotoxicity with serial echocardiography is not a recognized methotrexate monitoring pathway.
Option D: Option D is incorrect: ototoxicity is not a characteristic methotrexate toxicity.
Option E: Option E is incorrect: methotrexate can cause pneumonitis, but monthly spirometry is not the primary surveillance strategy and the dominant chronic toxicity is hepatic.
23. [CASE 6 — QUESTION 3]
Continuing with the same patient. While hypothetically on methotrexate, A.B. develops worsening renal function during an intercurrent illness. Given methotrexate's elimination route, what should the clinician anticipate and do?
A) Methotrexate clearance will rise as renal function declines, so the dose should be increased
B) Renal function is irrelevant to methotrexate handling, so no change is needed
C) Declining renal function shifts methotrexate to hepatic elimination, removing any cytopenia risk
D) Renal impairment accelerates conversion of methotrexate to an inactive metabolite, so toxicity falls
E) Because methotrexate is predominantly renally eliminated, a falling glomerular filtration rate causes it to accumulate and raises cytopenia risk; methotrexate is contraindicated once estimated glomerular filtration falls below about 30 mL/min/1.73m2, so it should be held and counts monitored
ANSWER: E
Rationale:
Methotrexate is cleared predominantly by the kidney, so a falling glomerular filtration rate reduces elimination and causes accumulation, increasing the risk of bone-marrow suppression and cytopenias. Methotrexate is contraindicated once estimated glomerular filtration falls below roughly 30 mL/min/1.73m2; with worsening renal function it should be held and blood counts monitored.
Option A: Option A is incorrect: declining renal function reduces clearance, so the drug accumulates and the dose should not be raised.
Option B: Option B is incorrect: renal function is central to methotrexate elimination and toxicity.
Option C: Option C is incorrect: methotrexate does not switch to hepatic elimination to rescue clearance; renal impairment raises exposure and cytopenia risk.
Option D: Option D is incorrect: renal impairment slows elimination of active drug rather than accelerating inactivation, so toxicity rises.
24. [CASE 6 — QUESTION 4]
Continuing with the same patient. A.B.'s case prompts a teaching discussion on how methotrexate and thiopurines are positioned across disease type and patient sex. Which summary is most accurate?
A) Methotrexate is the preferred maintenance agent in ulcerative colitis, and thiopurines are ineffective there
B) Disease type and sex are irrelevant; the agents are fully interchangeable in all settings
C) Thiopurines are preferred for ulcerative colitis maintenance because methotrexate lacks proven efficacy in ulcerative colitis; in Crohn's disease both are acceptable, with methotrexate often favored in men because of the higher thiopurine-associated lymphoma risk in that group and less preferred in women of reproductive age because of teratogenicity
D) Thiopurines are contraindicated in Crohn's disease, leaving methotrexate as the only option
E) Methotrexate is preferred in women of reproductive age because of a favorable pregnancy profile
ANSWER: C
Rationale:
The positioning differs by disease and patient factors. In ulcerative colitis, methotrexate lacks proven maintenance efficacy, so thiopurines are preferred. In Crohn's disease, methotrexate and thiopurines have comparable steroid-sparing efficacy; methotrexate is often favored in men because the thiopurine-associated non-Hodgkin lymphoma risk is higher in men, and it is less preferred in women of reproductive age because of teratogenicity—consistent with choosing a thiopurine for A.B.
Option A: Option A is incorrect: it reverses the ulcerative colitis evidence; methotrexate is the weaker agent there and thiopurines are effective.
Option B: Option B is incorrect: disease type and sex clearly influence the choice.
Option D: Option D is incorrect: thiopurines are effective maintenance agents in Crohn's disease, not contraindicated.
Option E: Option E is incorrect: methotrexate's pregnancy profile is unfavorable, so it is not preferred in women of reproductive age.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.